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Personalized Medicine and Patient Privacy Concerns in the Telemedicine Age1 
Kevin E. Noonan, Ph.D.2 
It is an ancient tradition in medical practice that a patient’s confidences must be 
respected and unauthorized disclosure of medical information be prohibited.3 This practice 
has become progressively more difficult to maintain as patients’ medical information has 
become collected in electronic media, which can be inherently more difficult to adequately 
secure.4  Complicating traditional privacy concerns is the extent of disclosure required by 
insurers (both public and private) to justify and coordinate coverage for medical care.5 This 
paper reviews efforts taken to date and on-going to enhance protection for medical 
information, particularly with regard to electronic databases containing such information.  
It also reviews trends in medical diagnostics and protections for such methods, in the face 
of judicial, policy, and public enmity towards restrictions thereof. 
1. Medical records privacy 
The principal Federal law protecting patient privacy in their medical records is the 
                                                        
1 Adapted from a talk, Kevin E. Noonan, Intellectual Property Issues in Telehealth, 2017 
Annual Jaharis Symposium, DePaul College of Law (Mar. 9, 2017). 
2 Partner, McDonnell Boehnen Hulbert & Berghoff LLP, Chicago, IL (www.mbhb.com) 
and founding author of the Patent Docs weblog, www.patentdocs.org. 
3 “Whatsoever things I see or hear concerning the life of men, in my attendance on the 
sick or even apart therefrom, which ought not be noised abroad, I will keep silence 
thereon, counting such things to be as sacred secrets.” See Greek Medicine: The 
Hippocratic Oath, U.S. NAT’L LIB. OF MED. (2012), 
https://www.nlm.nih.gov/hmd/greek/greek_oath.html. 
4 Feisal Nanji, Security Challenges of Electronic Medical Records, COMPUTERWORLD 
(Feb. 19, 2009), https://www.computerworld.com/article/2531320/security0/security-
challenges-of-electronic-medical-records.html. 
5 See Improved Care Coordination: The Need for Better Improved Care Coordination, 
HEATHIT.GOV, (Mar. 20, 2014), https://www.healthit.gov/providers-
professionals/improved-care-coordination. 
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Health Insurance Portability and Accountability Act of 1996, or HIPPA. 6   This Act 
provides national standards for electronic health care transactions and, having been enacted 
prior to digitalization of most medical records was initially concerned with the accessibility 
of medical records tied to reimbursement.7 The law is administered under the Office of 
Civil Rights for HIPAA as part of the U.S. Department of Health and Human Services8 
and also codifies responsibility for maintaining the confidential status of patient electronic 
medical records.9  
With the advent of electronic medical record-keeping and “telemedicine,” HIPAA 
requires a clinician involved in telemedicine has the same duty to safeguard a patient’s 
medical records and keep their treatments confidential as a traditional physician. 10 
Operationally, this involves ensuring that both the place confidential information resides 
and where it is stored must be secure and no confidential patient information exposed 
inadvertently or otherwise.11 This is particularly relevant due to the potential for such 
exposure, particularly by technical personnel who can act more independently of the 
medical team than in traditional medical settings (where the records are conventionally 
kept on-site in a physician’s office or hospital records repository with all the attendant 
security related to other aspects of the practice such as access to drugs).  In addition and 
unique to electronic medical record keeping, a patient’s confidential medical information 
                                                        
6 Health Insurance Portability and Accountability Act (“HIPAA”) of 1996, Pub. L. No. 
104-191, 110 Stat. 1936 (1996). 
7 42 U.S.C. § 1320a-7c (2010).  
8 U.S. Dep’t of Health & Human Serv., https://www.hhs.gov/ocr/index.html. 
9 42 U.S.C. § 1320a-7c (2010). 
10 45 C.F.R. § 160.202 2007. 
11 42 U.S.C. § 1320a-7c (2010). 
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is subject to potential exposure from hackers during transmission or storage;12 this risk 
requires at a minimum some form of encryption to prevent information from being 
inappropriately accessed.13 
The law identifies three groups of individuals who have responsibility for 
maintaining the confidentiality of patient medical records and other information: 
▪ A covered healthcare provider, who is a person, business or agency that 
furnishes, bills, or receives payment for health care in the normal course of 
business and transmits any covered transaction electronically14 
 
▪ A health care clearinghouse, which is a business or agency that processes 
or facilitates the processing of health information from a nonstandard 
format or content into a standard format or vice versa, or the business or 
agency performs this function for another legal entity15 
 
▪ A private benefit plan, which is a plan for an individual, group or some 
combination thereof, and provides or pays for the cost of medical care, 
having greater than 50 participants and that is not self-administered16 
 
Also included under the umbrella of HIPAA responsibility for maintaining patient 
confidentiality are “business associates,” which comprise anyone that: 
▪ Creates, receives, maintains, or transmits protected health information 
(PHI) to perform certain functions or activities on behalf of a covered entity;  
 
▪ Provides legal, actuarial, accounting, consulting, data aggregation, 
management, administrative, accreditation, or financial services to, or for, 
a covered entity in situations where PHI is involved;  
▪ Provides data transmission services to a covered entity and has access to 
PHI on a routine basis;  
 
                                                        
12 U.S. Dep’t. of Health & Human Serv. (2013), https://www.hhs.gov/hipaa/for-
professionals/security/laws-regulations/index.html. 
13 See Elizabeth Snell, Breaking Down HIPAA: Health Data Encryption Requirements, 
HEALTHITSECURITY.COM (Mar. 20, 2015), https://healthitsecurity.com/news/breaking-
down-hipaa-health-data-encryption-requirements.  
14 HIPAA § 262, 42 U.S.C. §§1320 d(3), 1320d-1. 
15 HIPAA § 262, 42 U.S.C. §§1320 d(2), 1320d-1. 
16 HIPAA § 262, 42 U.S.C. §§1320 d(5), 1320d-1. 
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▪ Offers personal health records to one or more individuals on behalf of a 
covered entity; and/or 
 
▪ Operates as a subcontractor of the business associate who has been 
delegated a function, activity, or service in a capacity other than as a 
member of the business associate’s workforce.17  
 
2. Genetic information privacy 
A particular facet of patient information related to health and subject to inadvertent 
disclosure is genetic information, which has become available and greatly increased in 
scope over the past 40 years.18 Today there are many more examples of diseases having a 
known genetic basis as well as diseases where the risk (and especially increased risk) of 
developing such diseases is being elucidated.19 Concerns that this information could be 
used to discriminate against individuals in employment or other social contexts (including 
access to health insurance) motivated passage of the Genetic Information 
Nondiscrimination Act (GINA) in 2008.20 The Act prohibits health insurers or health plan 
administrators from requesting or requiring genetic information of an individual or the 
individual’s family members, or using it for decisions regarding coverage, rates, or 
preexisting conditions. 21  The law also prohibits most employers from using genetic 
                                                        
17 See 45 C.F.R. §§ 164.502(e), 164.504(e). 
18 Previously, only a handful of illnesses and propensities were known to have a genetic 
basis.  These include diseases related to chromosomal abnormalities, such as Down’s 
Syndrome, Turner’s Syndrome, and Klinefelter’s syndrome, and those related to genetic 
mutations, including sickle cell anemia, cystic fibrosis, Duchenne’s muscular dystrophy, 
and Tay-Sachs disease. See H. Chial, Rare Genetic Disorders: Learning About Genetic 
Disease Through Gene Mapping, SNPs, and Microarray Data, 1 NATURE EDUC. 192 
(2008).  
19 These diseases include (most (in)famously) increased risk for breast and ovarian cancer 
associated with mutations in the BRCA gene, as well as Huntington’s chorea and familial 
adenomatous polyposis. 
20 Pub. L. 110-233, 122 Stat. 881 (2008). 
21 Id. 
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information for hiring, firing, or promotion decisions, and for any decisions regarding 
terms of employment.22 GINA’s health coverage non-discrimination protections do not, 
however, extend to life insurance, disability insurance and long-term care insurance,23 nor 
does the Act mandate coverage for any particular test or treatment.24 The size of a company 
also limits access to GINA protections: GINA’s employment provisions generally do not 
apply to employers with fewer than 15 employees.25 The impact on GINA for health 
coverage is limited, and the law is aimed primarily at protecting individuals from 
discrimination based on their genetic heritage.26 This is important because GINA does not 
prohibit health insurers or health plan administrators from obtaining and using genetic test 
results in making health insurance payment determinations (which could form an economic 
basis for such discrimination).27 
3. Further protections based on technological developments 
As technology has developed the capacity and propensity for new and unexpected 
vulnerabilities for patients’ confidential health information have increased concomitantly.  
                                                        
22 Id.; there can be exceptions where a genetic condition or propensity is directly related 




26Genetic Information Nondiscrimination Act of 2008, Pub. L. No. 110-233, 122 Stat. 
881 (2008); For example, for health coverage provided by a health insurer to individuals, 
GINA does not prohibit the health insurer from determining eligibility or premium rates 
for an individual based on the manifestation of a disease or disorder in that individual. 
For employment-based coverage provided by group health plans, GINA permits the 
overall premium rate for an employer to be increased because of the manifestation of a 
disease or disorder of an individual enrolled in the plan, but the manifested disease or 
disorder of one individual cannot be used as genetic information about other group 
members to further increase the premium. 
27 Id. 
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Accordingly, Congress has seen fit to expand legal protections for patient health records; 
the most recent example of such laws is the Health Information Technology for Economic 
and Clinical Health Act of 2009 (the HITECH Act).28 This Act provides subsidies for 
using/creating electronic health records and expands privacy and security provisions of 
HIPAA.29 These HIPAA expansions include direct regulation of business associates (as 
defined under HIPAA) and application of HIPAA’s privacy and security rules to such 
entities.30 The HITECH Act also dramatically increases the required response to breaches 
of PHI and the enforcement of such requirements, including notification, patient access to 
information regarding breaches to the confidentiality of their records, and civil and criminal 
penalties, where appropriate, for breach.31 
Compliance with these various statutes is not something intrinsic to electronic 
medical record-keeping systems but is exquisitely dependent on how they are 
implemented.  In assessing compliance (or designing systems to ensure compliance), it is 
important to distinguish having information that identifies patients for some purposes (such 
as billing, diagnosis, or treatment) but not for others (disclosing personal information 
outside the scope of patient confidentiality). Efforts to ensure compliance include 
agreements (ultimately, contracts) between medical personnel (doctors, nurses, other 
practitioners) who generate medical information and technical actors (database 
administrators and technical personnel), wherein the parties acknowledge their 
                                                        
28 American Recovery and Reinvestment Act of 2009, Pub. L. No. 111-5, 123 Stat. 226 
(2009). 
29 Id. at Subtitle C. 
30 Id. at Subtitle D. 
31 Id. 
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responsibilities and agree to behave in a HIPAA-compliant manner.32 The existence of 
such agreements can raise awareness amongst all actors involved in producing and 
cataloging patient health information, and can avoid post-hoc claims of inadvertence while 
ensuring appropriate ascribing of liability for data breach (and perhaps minimizing the 
likelihood that breach and liability for breach will ensue).  These efforts are important 
because personal health information disclosure is often irremediable to all parties. 
4. Privacy concerns 
Personal medical health records fall well within the modern expansion of privacy 
protected under the First Amendment,33 as well as under interpretations (conventional as 
well as modern) of the Third, Fourth, Fifth, and Fourteenth Amendments.34 Given the 
intimate nature of medical information, these privacy concerns, a patient’s medical records 
and other health information involve equivalent concerns regarding protections against 
publicity of this information as motivated protection of other areas of individual privacy.  
These protections are frankly directed to a citizen’s protection from government intrusion, 
however.  Protections from private actors (including employer and the press, among others) 
must rely on other power of Congress, such as its power over interstate commerce.  This 
type of interest certainly applies to the use of medical information regarding employment 
and, particularly in view of nationwide insurance providers (despite local control thereof 
state-by-state) and similar consolidation of the medical provider industry (hospitals, for 
                                                        
32 Ultimately, of course, such agreements have their greatest impact on how blame for 
medical records data breaches are assessed, but having the agreement itself can raise 
awareness of the risks and responsibilities involved. 
33 See Griswold v. Connecticut, 381 U.S. 479 (1965).  
34 All these amendments more or less directly implicate the privacy right for an individual 
to be secure in her home or in her possessions and to restrict the government’s ability to 
intrude on that privacy by requiring due process of law to do so. 
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example).  These privacy rights can be functionally if not legally limited when pitted 
against free speech and press freedom rights under the First Amendment; remedies for 
unauthorized disclosure in such cases may be cabined within traditional libel, slander, 
rights of publicity and breach of confidentiality actions (albeit these will be more attenuated 
for individuals who have purposefully placed themselves in the public eye, such as actors, 
musicians, and other artists, as well as politicians).35 
 5. Ownership of patient medical record databases 
Patient medical information is contained in electronic databases. Even in the analog 
age, there was a recognition that the accumulation of individual items of data in a collection 
was not only valuable but could be protected as a form on intellectual property.36  Books 
of telephone listings and maps (particularly for cities and towns) could be protected by 
copyright, and more particularized lists (such as a company’s client or customer lists) were 
valuable trade secrets.37 The value of this type of intellectual property was not in its 
individual items but in the collection; in this way such traditional databases (which is what 
we would recognize them to be, especially when reduced to electronic media) differ from 
collections of patient medical information, in which each item represents a person’s 
                                                        
35 See New York Times Co. v. Sullivan, 376 U.S. 254 (1964). 
36 See Julie E. Cohen & William M. Martin, Intellectual Property Rights in Data, INFO. 
SYS. & THE ENV’T (2001), https://www.nap.edu/read/6322/chapter/5. Protecting 
databases has traditionally not been a particularly attractive option, because among other 
things it relied on trade secret legislation enacted state-by-state.  This changed when 
Congress enacted the Defend Trade Secrets Act in 2016 (Pub. L. 114-153, 130 Stat. 376 
(2016), codified at 18 U.S.C. § 1836 et seq.); see also Josh Rich, President Obama Signs 
Defend Trade Secrets Act, PATENT DOCS (May 11, 2016), 
http://www.patentdocs.org/2016/05/president-obama-signs-defend-trade-secrets-
act.html#comments. 
37 See Timothy K. Sendek, Customer Lists as Trade Secrets, NAT’L L. REV. (Dec. 30, 
2009), https://www.natlawreview.com/article/customer-lists-trade-secrets. 
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medical history and (in some instances) propensity for developing a disease. 38  The 
technology involved in creating or storing information (either per se or related to physical 
samples) can be protected (by patenting39 or less productively as a trade secret40).41  But 
databases themselves are difficult to protect  because each new entry creates a new database 
not described before.42  
Like traditional trade secret collections, protecting medical information databases 
involves restricting access, which is the key property right. 43  This can be limited to 
interrogating a portion or subset of the items in the database or can provide have access to 
the entirety of the information therein. 44  One of the negative consequences of such 
protection can be academic research, insofar as the database owner restricts access.  
                                                        
38 This value being demonstrated by the protections for these items as discussed above; 
Sendek, supra note 37. 
39 Patenting and trade secret protection are not necessarily mutually exclusive. Most 
inventions are kept confidential (i.e., are trade secrets) until a patent application is 
published. Moreover, a product can have some aspects patented and others kept as trade 
secrets (provided the best mode requirement of 35 U.S.C. § 112(a) is not violated); See 
Christianson v. Colt Indus. Operating Corp., 486 U.S. 800 (1988). 
40 Although trade secret protection can lead to substantial judgments. See, e.g., Epic 
Systems Corp. v. Tata Consultancy Servs., Ltd., No. 14-cv-748-wmc, 2016 U.S. Dist. 
LEXIS 50157 (W.D. Wis. Apr. 14, 2016) ($240 million compensatory damages, $700 
million punitive damages); GM v. Ignacio Lopez de Arriortua, 948 F. Supp. 656 (E.D. 
Mich. 1996) ($1.1 billion judgment: $100 million cash, $1 billion products); and 
Pacesetter v. Nervicon, No. BC424443 (Cal. Superior Ct. 2011) ($947 million judgment).  
41 See USPTO Classification Schedule, Class 707, Subclasses 600-831 (Jan. 2010), 
https://www.uspto.gov/web/patents/classification/uspc707/sched707.htm. 
42 Each iteration of a database created by adding a new entry creates a new database and 
thus, defeats an applicant’s ability to satisfy at least the written description requirement of 
35 U.S.C. § 112(a). See, by analogy, In re Alonso, 545 F.3d 1015 (Fed. Cir. 2008). 
43 This is true even for collections of biological samples or organisms (which are often 
individually not patentable) such as those curated by the American Type Culture 
Collection (www.atcc.org).   
44 This is true whether the collection is physical (such as biological or other specimens) 
or just lists (pure information). 
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Fortunately, this rarely happens.45 
6. The uncertain future of patent protection for human diagnostics 
One advantage of accumulating databases of patient medical information is that, 
with sufficient size, patterns of relationships on inheritance46 or environmental exposure47 
can become evident.  This has been the experience of the past 40 years, particularly with 
regard to identifying genes (and in particular genetic mutations or other variants) that are 
involved with and provide predictive power for certain diseases. 48  The continued 
                                                        
45 An example of how database access can provide competitive advantages even without 
patent protection is the Myriad Genetics database for BRCA gene mutations. As is well 
known, Myriad’s patents on isolated human BRCA genes BRCA1 and BRCA2 were 
invalidated by the Supreme Court in 2013.  Ass’n for Molecular Pathology v. Myriad 
Genetics, Inc., 133 S. Ct. 2107 (2013), and patent protection for methods of detecting 
such mutations lost when the Court of Appeals for the Federal Circuit invalidated such 
claims on appeal from consolidated actions for infringement brought by Myriad against 
several genetic diagnostic providers in the wake of the Supreme Court decision. In re 
BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 774 F.3d 755 (Fed. Cir. 
2014).  Nevertheless, Myriad has been able to protect its competitive advantage in the 
BRCA testing market because its extensive database (estimated to contain the results 
from more than 3 million patients) enables Myriad to provide informative diagnostic 
information with regard to genetic variants that occur with sufficient infrequency (termed 
“variants of unknown significance” or “VUS”) that their association with predicted 
disease is unclear without reference to Myriad’s database. 
46 Indeed, one advantage University of Utah researchers enjoyed in the competition 
between several laboratories to isolate the human BRCA genes was the records, going 
back more than 100 years, of death and causes of death for generations of ancestors.  
Because breast and ovarian cancers were well recognized during this time period, 
classical genetic methods could be combined with modern molecular biological 
approaches to identify the portions of chromosome 17 (BRCA1) and chromosome 13 
(BRCA 2) where these loci could be found. See, Jeff M. Hall et al., Linkage of early-
onset familial breast cancer to chromosome 17q21, 250 SCIENCE 1684–1689 (1990); 
Richard Wooster et al., Localization of a breast cancer susceptibility gene, BRCA2, to 
chromosome 13q12-13, 265 SCIENCE 2088–90 (1994). 
47 See, John B. Whitfield et al., Genetic Effects on Toxic and Essential Elements in 
Humans: Arsenic, Cadmium, Copper, Lead, Mercury, Selenium, and Zinc in 
Erythrocytes, 118 ENVTL. HEALTH PERSP. 776, 776-82 (2010). 
48 For example, the BRCA genes for breast and ovarian cancer (U.S. Patent Nos. 
5,747,282 and 5,837,492); repetitive motif expansion in Duchenne’s muscular dystrophy 
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accumulation of this evidence is expected (and intended) to result in individual-centric 
medicine (termed “personalized medicine”), i.e., by knowing an individual’s genotype for 
genes involved in disease or treatment of disease will permit treatment of the individual 
rather than what has been developed for a population.49 
Many of these diagnostic methods have been heretofore the subject of patent 
protection. 50  Patents, in the U.S., are defined by statute; this includes what types of 
inventions are eligible for patenting, which is codified in the patent statute under Section 
101.51 Until recently this statutory requirement has been construed broadly to include 
“anything under the sun made by man.”52 However, the scope of patent subject matter 
eligibility has always been constrained by exceptions recognized by the Supreme Court; 
                                                        
(M. Koenig et al., The complete sequence of dystrophin predicts a rod-shaped 
cytoskeletal protein, 53 CELL 219, 219–26 (1988); M. Koenig et al., The molecular basis 
for Duchene versus Becker muscular dystrophy: correlation of severity with type of 
deletion. 45 AM. J. HUMAN GENET. 498, 498–506 (1989)) and Fragile X syndrome 
(Kathryn B. Garber et al., Fragile X syndrome, 16 EUROPEAN J. OF HUMAN GENETICS 
666, 666–72 (2008)); and deletion of a specific amino acid (Phe508) in cystic fibrosis 
(J.M. Rommens et al., Identification of the cystic fibrosis gene: chromosome walking and 
jumping, 245 SCIENCE 1059, 1059-65 (1989)). 
49 “[T]herapy with the right drug at the right dose in the right patient.” Laviero L. 
Mancinelli et al., Pharmacogenomics: The Promise of Personalized Medicine, 2 AAPS 
PHARMSCI 29, 29-41 (2000).  Personalized medicine is expected to provide the ability to 
make more informed medical decisions and result in a higher probability of desired 
outcomes thanks to better-targeted therapies and a reduced probability of negative side 
effects.  Unlike in traditional medicine, personalized medicine is focused on prevention 
and prediction of disease rather than reaction to it and earlier disease intervention than 
has been possible in the past.  Another expected benefit is to reduce healthcare costs.   
50 See U.S. Patent Nos. 5,747,282 (BRCA 1); 5,837,492 (BRCA 2); 5,187,063 
(Duchenne’s muscular dystrophy); and 6,107,025 and 6,180,337 (Fragile X syndrome), 
among others. 
51 “Whoever invents or discovers any new and useful process, machine, manufacture, or 
composition of matter, or any new and useful improvement thereof, may obtain a patent 
therefor, subject to the conditions and requirements of this title.” 35 U.S.C. § 101. 
52 Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980). 
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these are “laws of nature, physical phenomena, and abstract ideas.”53 
With regard to claims to diagnostic methods, they adopt a canonical format of 
reciting steps to “determine and infer”: one or more steps involve detecting something (e.g., 
a biomarker) and from that inferring something related to what is detected (e.g., the 
presence or absence of a disease).54 As a consequence, unlike industrial and chemical 
method claims,55  diagnostic methods claim to produce information, i.e., the inference 
related to what is detected.56 In addition, for medical diagnostics claims, patent protection 
implicates public policy concerns involving whether permitting patenting will inhibit the 
practice of medicine or interfere with a physician treating a patient as a result of obtaining 
a diagnostic result.57 
These concerns apparently prompted a series of decisions by the U.S. Supreme 
Court severely restricting patent eligibility to medical diagnostic methods. 58  These 
decisions mandate that claims that merely recite a law of nature and supply the direction to 
“apply it” are not patent eligible.59 The law as interpreted by the Court requires the claim 
to recite (and the specification to disclose) “something more” than the law of nature, and 
that “something more” must be more than what is “well-understood, routine, and 
                                                        
53 Id. 
54 Kevin Emerson Collins, Prometheus Laboratories, Mental Steps, and Printed Matter, 
50 HOUSTON L. REV. 391, 394 (2013). 
55 The practice of these types of method claims produce a device or other tangible 
product; see Diamond v. Diehr, 450 U.S. 175 (1981). 
56 See Kevin E. Noonan, Rapid Litigation Management Ltd. v. Cellzdirect, Inc. (Fed. Cir. 
2016), PATENT DOCS (July 6, 2016), http://www.patentdocs.org/2016/07/rapid-litigation-
management-ltd-v-cellzdirect-inc-fed-cir-2016.html. 
57 Mayo Collaborative Servs. v. Prometheus Labs., Inc., 566 U.S. 66, 68, 91 (2012). 
58 Id. at 66. 
59 Id.  
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conventional.”60 Further, it is not enough to inform a relevant audience about certain laws 
of nature, and add steps that “consist of well­understood, routine, conventional activity 
already engaged in by the scientific community; and those steps, when viewed as a whole, 
add nothing significant beyond the sum of their parts taken separately” according to the 
Court. 61  Many courts have followed this reasoning to invalidate claims to medical 
diagnostic methods.62 
In addition to the courts, the U.S. Patent and Trademark Office has adapted its 
practices for determining patent eligibility to be compliant with the Court’s instructions.  
This has resulted in a two-step approach (Figure 1)63, as follows: 
1. Is the claim is directed to a “natural law” that is subject to a § 101 analysis? 
2. A) Is the claim directed to a patentable “judicially recognized exception” 
under Mayo/Alice? 64  (step 2A); and if yes, B) does the claim recite 
“additional elements that amount to significantly more than the judicial 
exception”? 
                                                        
60 Id. at 79-80. 
61 Id.  
62 Particularly vulnerable have been claims that recite “a method for diagnosing disease 
X, by detecting the (presence/absence/changed amount) of marker 
(gene/protein/metabolite) Y.” Approximately 70% of all patents challenged under 
Mayo/Alice are found invalid, comparison over 11,000 granted claims. The worst districts 
for patentees (10 or more §101 decisions) have been the Districts of Delaware, California 
(Northern), California (Central) (>70% invalid), while the best district for patentees has 
been the Eastern District of Texas (<35% invalid). 
63 2014 Interim Eligibility Guidance Quick Reference Sheet, U.S. PATENT & TRADEMARK 
OFFICE (2014), 
https://www.uspto.gov/sites/default/files/documents/2014_eligibility_qrs.pdf. The test 
consists of three steps, designated by the Office as Step 1, Step 2a and Step 2b. 
64 The Court’s Mayo decision was further explicated, and its reasoning explained, in a 
decision unrelated to patent eligibility of diagnostic method claims.  See Alice Corp. Pty. 
v. CLS Bank Int’l., 134 S. Ct. 2347, 2354 (2014). 
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The USPTO then proceeds with examination for patentability, applying the “broadest 
reasonable interpretation” of the claims after conducting the subject matter eligibility 
analysis under these rubrics.65 When applying the test of what satisfies the requirement for 
what is “significantly more,” the Office applies the standard that “the elements of the claim, 
considered both individually and as an ordered combination, are sufficient to ensure that 
the claim as a whole amounts to significantly more than the exception itself.”66  As in many 
USPTO analyses, the claims must be considered as a whole.67  In practice, the USPTO’s 
implementation of these Supreme Court decisions have severely limited patenting of 
diagnostic method claims68 and set back progress in the development of personalized 
medicine.69 
                                                        
65 Memorandum from Robert W. Bahr, Deputy Commissioner for Patent Examination 
Policy, to the Patent Examining Corps., USPTO (May 4, 2016), 
https://www.uspto.gov/sites/default/files/documents/ieg-may-2016-memo.pdf 
[hereinafter “Bahr Memo”]. 
66 Id.; the Guidances for applying this standard include the note that “[i]ndividually-
viewed elements may not appear to add significantly more, those additional elements 
when viewed in combination may amount to significantly more than the exception.” Id.  
67 Id. 
68 See Heidi Ledford, US Personalized-Medicine Industry Takes Hit from Supreme Court, 
536 NATURE 382 (2016). Summary of Intellectual Property Scholars Conference, 
presenting data that after Mayo, USPTO was more than four times more likely to reject 
personalized medicine claims as ineligible and applicants were only half as likely to 
overcome the rejections.  Statistically, 5.5% of applications were rejected under § 101 
rejections in 2011 and the percentage of applications rejected under § 101 had risen to 
22.5% in 2015.  Before Mayo, 70.7% of § 101 rejections were overcome but that 
percentage had fallen to 29.7% by 2015.  Assuming 1,000 claims, this corresponds to 55 
claims being rejected, 39 rejections overcome and 16 maintained prior to the Mayo 
decision and 225 claims rejected, 67 overcome, and 158 maintained after the Mayo 
decision was rendered.  This represents an almost ten-fold increase in diagnostic method 
claims being rejected by USPTO.  
69 Bernard Chao & Amy Mapes, An Early Look at Mayo’s Impact on Personalized 
Medicine, 2016 PATENTLY-O PATENT L. J. 10-14 (2016).  This report reviewed one of 
every ten applications in USPTO Art Unit 1634 (methods for measuring or testing 
processes involving enzymes or microorganisms).  Only subject matter eligibility 
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Recent Guidance from the USPTO advises that detection methods using novel 
reagents or detection methods are patent eligible, as are novel treatment methods and 
specific treatment methods using particular administration routes or methods.70 Somewhat 
controversially, the Guidance also indicates that methods of detecting a biomarker that 
does not recite a diagnostic correlate would also be patent eligible, a policy decision 
seemingly at odds with at least one Federal Circuit opinion.71 Patent ineligible methods 
according to the USPTO’s interpretation of the Supreme Court’s Mayo/Alice formula are 
diagnostic treatment methods broadly reciting a natural law (defined as the correlation 
between a marker and disease); claims that recite mental steps of drawing the inference 
regarding the outcome of a diagnostic method and the diagnosis; or claims reciting a higher 
level of generality between the biomarker and a diagnosis.72 
                                                        
rejections were considered, and their results showed that of the 294 applications 
considered, 170 (58%) were abandoned, 53 patented, 3 allowed, and 2 on appeal (only 1 
of which involved a §101 rejection).  Since the time of the study, 196 (67%) have been 
abandoned, 64 granted, 1 allowed and 1 on appeal (the Examiner having been affirmed in 
the prior appeal). A random spot check of the newly abandoned and patented claims 
revealed that no continuing applications were filed in the abandoned applications and 
narrow claims (e.g., requiring very specific reagents or a treatment step) were allowed in 
the grated patents. 
70 See Bahr Memo, supra note 65; see also Subject Matter Eligibility Examples: Life 
Sciences, USPTO (May 2016), https://www.uspto.gov/sites/default/files/documents/ieg-
may-2016-ex.pdf.  
71 See Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015), cert. 
denied, 136 S. Ct. 2511 (2016). 
72 Such claims are exemplified by claims invalidated by the district court, and affirmed 
by the Federal Circuit.  For example, claim 1 of U.S. Patent No. 5,709,999: 
A method for detecting a germline alteration in a BRCA1 gene, said alteration 
selected from the group consisting of the alterations set forth in Tables 12A, 14, 18 
or 19 in a human which comprises analyzing a sequence of a BRCA1 gene or 
BRCA1 RNA from a human sample or analyzing a sequence of BRCA1 cDNA 
made from mRNA from said human sample with the proviso that said germline 
alteration is not a deletion of 4 nucleotides corresponding to base numbers 4184-
4187 of SEQ ID NO:1 
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Related to the Court’s views on medical diagnostic claims, the Justices have also 
rendered decisions on the patent eligibility of natural products.73 There have been few court 
cases on this aspect; however, in addition to UURF v. Ambry Genetics,74 the Federal Circuit 
invalidated claims to chimeric sheep in In re Rosyln75 but declared patent-eligible claims 
for producing in vitro hepatocyte cultures.76 These decisions are relevant to patenting 
biomarkers,77  the prospects for which (at least with regard to unaltered embodiments 
thereof) have dimmed in the aftermath of the Supreme Court’s Myriad decision. This is 
because, by their nature, many of the relevant, diagnostically informative biomarkers are 
                                                        
Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 
181, 192–211 (S.D.N.Y. 2010). 
73 Ass’n for Molecular Pathology, 569 U.S. at 576; Surprisingly, the Court had not 
directly spoken on the question of subject matter eligibility for natural products until its 
Myriad decision. 
74 In re BRCA1- & BRCA2-Based Hereditary Cancer Test Patent Litig., 774 F.3d at 755; 
in this aspect of the decision the Federal Circuit invalidated claims to primer pairs for in 
vitro amplifying portions of the human BRCA genes informative for genetic diagnostics 
predicting the likelihood of developing breast or ovarian cancer.  
75 In re Roslyn Inst. (Edinburgh), 750 F.3d 1333 (Fed. Cir. 2015); the appellate court’s 
decision relied on the fact that the claimed sheep were, indeed, sheep (albeit genetically 
identical to the sheep from which they were produced by in vitro nuclear transfer to 
enucleated eggs).  It is undetermined whether other ways to distinguish the claimed 
product would be patent eligible (for example, a claim to a genetically identical flock of 
sheep). 
76 Rapid Litig. Mgmt. Ltd. v. Cellzdirect, Inc., 827 F.3d 1042 (Fed. Cir. 2016); a non-
trivial distinction between the claims at issue in this case and diagnostic method claims 
invalidated in other decisions is that these claims have a tangible outcome (the in vitro 
hepatocyte cultures produced by the claimed methods) as opposed to intangible 
diagnostic information produced by conventional medical diagnostic claims. 
77 Examples of these molecules include those that are nucleic acid-based (e.g., single 
nucleotides polymorphisms or SNPs, and chromosomal rearrangements); protein-based 
(e.g., sickle cell anemia); immunological (antigens, antibodies, cytokines); metabolites 
(endogenous or produced in response to drugs, diet, etc.); and more complex phenotypes. 
See Alkes L. Price et al., Progress and promise in understanding the genetic basis of 
common diseases, 282 PROC. R. SOC. B 20151684. 
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natural products,78 and the reasoning behind the Court’s Myriad decision suggests that 
mere isolation is not enough to confer patent eligibility to such molecules.79 What may be 
needed (suggested by the Myriad decision) is that whatever is claimed has somehow been 
changed from how it exists in nature;80 the safest course may be by a structural change to 
the biomarker, most typically by being conjugated or otherwise labeled with a detectable 
marker.81 
In the USPTO, recent Guidance82 has set forth examples of what is considered 
                                                        
78 While no court has rendered a decision affirming this characterization, the language of 
the Court’s Myriad opinion suggests that conventionally patent eligible molecules 
(antibiotic, antibodies, vitamins, vaccines, etc.) may not remain patent eligible. 
79 The Court’s Myriad decision held that genomic DNA (or indeed any DNA molecule 
that had the structure found in a human chromosome) was patent ineligible because it had 
not been sufficiently changed from how it occurred in nature to evidence the “hand of 
man” as set forth in the Court’s Chakrabarty decision. Diamond v. Chakrabarty, 447 
U.S. 303, 310 (1980). Complementary DNA (cDNA), produced by reverse transcription 
of messenger RNA could be eligible under the Court’s decision, provided it showed such 
differences; in higher organisms like man, for example, most cDNAs differ from the 
corresponding genomic DNA progenitors because so-called intervening DNA (or introns) 
have been spliced out during mRNA maturation.   It is clear that the Court recognized the 
need for human intervention to produce cDNA from mRNA; it is less clear that the Court 
appreciated that removing intron sequences (a process known as splicing; Dean H. Hamer 
& Philip Leder, Splicing and the formation of stable RNA, 18 CELL 1299, 1299-1302 
(1979)) was naturally performed inside the cell. Ass’n for Molecular Pathology, 113 S. 
Ct. at 2109.  
80 Purification or increased concentration or potency may not be enough, however. Id.  
81 While such distinctions have formed the basis for USPTO policy on natural products 
patenting, it must be recognized that many structural alteration have the capacity or 
likelihood to alter relevant biological activity (binding specificity or affinity, biological 
half-life, antigenicity, etc.). Id. 
82 Earlier iterations of such Guidances were criticized for being overly exclusive of patent 
eligibility.  For example, gunpowder was deemed ineligible has being merely a mixture 
of elemental sulfur, charcoal and saltpeter (KNO3), until it was pointed out that the 
mixture (but not combination of its components) had the capacity to explode.  In addition, 
review of 1355 drugs approved by the FDA from 1980-2010 indicated that the majority 
of anticancer drugs (80%) and antibiotic drugs (75%) would be patent ineligible under 
the earlier standards promulgated by the USPTO in response to the Supreme Court’s 
Mayo and Myriad decisions. See David J. Newman & Gordon M. Cragg, Natural 
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patent eligible and what is not for both diagnostic method claims and natural products.83 
For “products of nature,” these include: products comprising alterations (e.g., mutations, 
chemical reactions, changes in structure or physical form) not found in nature; formulations 
(particularly with components not found together in nature) that change properties or 
functional characteristics of product of nature; and nonconventionality of other aspects of 
the claimed invention (microneedles used for vaccination being exemplified in the 
Guidance).84 On the other hand, products of nature per se (i.e., having no differences except 
concentration or specific activity from their presence in nature);85 and combination of 
product of nature with other substances that do not change physical properties or other 
characteristics.86 Nevertheless, diagnostic reagents per se are likely to be ineligible, and 
according to the Court’s Myriad decision merely producing a reagent synthetically will not 
render claims to the reagent patent eligible provided that the structure is the same as exists 
                                                        
Products as Sources of New Drugs over the 30 Years from 1981 to 2010, 75 J. NAT. 
PROD. 311, 311-35 (2012). 81 Fed. Reg. 27381 (May 6, 2016). 
83 May 2016 Subject Matter Eligibility Update, 81 Fed. Reg. 27381 (May 6, 2016), 
https://www.gpo.gov/fdsys/pkg/FR-2016-05-06/pdf/2016-10724.pdf [hereinafter “May 
2016 Subject Matter Eligibility Update”]. See Kevin E. Noonan, USPTO Releases 
Memorandum on Subject Matter Eligibility, PATENT DOCS (July 18, 2016), 
http://www.patentdocs.org/2016/07/uspto-releases-memorandum-on-subject-matter-
eligibility.html#comments; see also Kevin E. Noonan, K., The Recent PTO Guidance on 
Subject Matter Eligibility: Lessons, PATENT DOCS (May 25, 2016), 
http://www.patentdocs.org/2016/05/the-recent-pto-guidance-on-subject-matter-eligibility-
lessons.html 
84See supra note 83. 
85 It is unclear whether a specific preparation at a therapeutically useful concentration 
would be patent eligible without more; it may be presumed that a pharmaceutical 
composition comprising excipients or other components would be considered a specific 
subset of patent-eligible formulations but there is no decision affirming this expectation. 
86 This reasoning relies expressly and heavily on the Supreme Court’s 1948 Funk 
Brothers Seed Co. v. Kalo Inoculant Co. decision (333 U.S. 127 (1948)), expressly 
reaffirmed in the Court’s Myriad decision after more than a generation of being ignored. 
 
  19 
in nature.87 
7. Conclusion 
Despite these challenges, it is uncontested that the application of technology to 
medical practice will continue (albeit its pace will likely be affected by whether such 
technologies can be protected, by patent, trade secret protection or otherwise).  With 
increased vulnerability of seemingly any information stored in electronic form, increased 
diligence in protecting patient information will need to be adopted if the legal and societal 




                                                        
87 Ass’n for Molecular Pathology, 113 S. Ct. at 2109. 
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Figure 1 
U.S. Patent and Trademark Office test for determining patent eligibility consists of three 
steps, designated by the Office as Step 1, Step 2a and Step 2b.88 
 
 
                                                        
88 2014 Interim Eligibility Guidance Quick Reference Sheet, U.S. PATENT & TRADEMARK 
OFFICE (2014), 
https://www.uspto.gov/sites/default/files/documents/2014_eligibility_qrs.pdf. 
